PVCT (Provectus Biopharmaceuticals) 3-1 Month Momentum %: 21.75% (As of Aug. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Provectus Biopharmaceuticals 3-1 Month Momentum %?

Provectus Biopharmaceuticals PVCT -4.00% 3-1 Month Momentum % is 21.75% as of Aug. 03, 2026. The stock has 3 warning signs investors should review. Among 1,389 Biotechnology companies, Provectus Biopharmaceuticals ranks better than 85.46% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-03), Provectus Biopharmaceuticals's 3-1 Month Momentum % is 21.75%.

The industry rank for Provectus Biopharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:

PVCT's 3-1 Month Momentum % is ranked better than
85.46% of 1389 companies
in the Biotechnology industry
Industry Median: -7.65 vs PVCT: 21.75

Provectus Biopharmaceuticals  (OTCPK:PVCT) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Provectus Biopharmaceuticals 3-1 Month Momentum % Related Terms

PVCT vs PSTV, ALGS, ATNM: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Provectus Biopharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Provectus Biopharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Provectus Biopharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Provectus Biopharmaceuticals's 3-1 Month Momentum % falls into.


Provectus Biopharmaceuticals  (OTCPK:PVCT) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 21.75% mean?
Provectus Biopharmaceuticals (PVCT) has a 3-1 Month Momentum % of 21.75% as of Aug. 03, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Provectus Biopharmaceuticals and its competitors. According to the industry distribution chart, Provectus Biopharmaceuticals ranks #202 out of 1389 companies in the Biotechnology industry, placing it in the top 14.5%.
Is Provectus Biopharmaceuticals' 3-1 Month Momentum % too high?
Provectus Biopharmaceuticals' current 3-1 Month Momentum % is 21.75%. Based on the distribution chart, Provectus Biopharmaceuticals ranks #202 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Provectus Biopharmaceuticals' 3-1 Month Momentum % compare to PSTV and ALGS?
According to the Biotechnology industry distribution chart, Provectus Biopharmaceuticals ranks #202 out of 1389 companies for 3-1 Month Momentum %. This places Provectus Biopharmaceuticals in the top 15% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Provectus Biopharmaceuticals and its competitors. Provectus Biopharmaceuticals's current 3-1 Month Momentum % is 21.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provectus Biopharmaceuticals stock overvalued right now?
Provectus Biopharmaceuticals (PVCT) has a current 3-1 Month Momentum % of 21.75%. The current 3-1 Month Momentum % is 21.75%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Provectus Biopharmaceuticals (PVCT), the current 3-1 Month Momentum % is 21.75% as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Provectus Biopharmaceuticals Business Description

Address 800 South Gay Street, Suite 1610, Knoxville, TN, USA, 37929
Provectus Biopharmaceuticals Inc is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases based on a class of bioactive synthetic small molecule halogenated xanthenes (HXs). Its flagship HX molecule is named rose bengal sodium (RBS). The company's proprietary, patented, pharmaceutical-grade RBS is the active pharmaceutical ingredient (API) in all its clinical development and non-clinical research programs. It has one operating and reporting segment, namely, the development of immunotherapy medicines.